Acutaas Chemicals Ltd

  • BSE Code : 543349
  • NSE Symbol : ACUTAAS
  • ISIN : INE00FF01025
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS

up-arrow 2,951.20 -49.20(-1.64%)

Open Price ()

2,997.00

Prev. Close ()

3,000.40

Volume (No’s)

333,925

Market Cap ()

24,161.81

Low Price ()

2,930.00

High Price ()

3,001.00

 

Board Meetings

Start Date End Date Purpose
27-Apr-2026 30-Apr-2026 Acutaas Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 inter alia to consider and approve the Audited Standalone & Consolidated Financial Results for the Fourth Quarter & Year ended on March 31 2026 and recommendation of final dividend as per details enclosed. The Board of Directors of the Company at their meeting held on Thursday , April 30, 2026, inter alia, considered & approved Audited Standalone & Consolidated Financial Results of the Company for the fourth quarter & year ended March 31, 2026. (As per BSE announcement dated on :30.04.2026)
21-Jan-2026 28-Jan-2026 Quarterly Results Acutaas Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2026 ,inter alia, to consider and approve Unaudited Standalone & Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2025 as per details attached. The Board of Directors of the Company at their meeting held on Wednesday, January 28, 2026, inter alia, considered & approved Unaudited Standalone & Consolidated Financial Results of the Company for the third quarter & nine months ended December 31, 2025 (As Per BSE Announcement Dated on: 28/01/2026) The Machine Readable/legible copy of the financial results for the quarter and nine months ended December 31, 2025 is being submitted. (As Per BSE Announcement Dated on:30.01.2026)
10-Oct-2025 17-Oct-2025 Acutaas Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended September 30 2025 as per details attached. The Board of Directors of the Company at their meeting held on Friday, October 17, 2025, inter alia, considered & approved Unaudited Standalone & Consolidated Financial Results of the Company for the second quarter & half year ended September 30, 2025. Unaudited financial results for the quarter and half year ended September 30, 2025 is enclosed. (As Per BSE Announcement Dated on:17.10.2025)
25-Sep-2025 25-Sep-2025 Board approved the allotment of 2200 equity shares of face value of Rs. 5/- each to the eligible employee of the Company as per details attached.
29-Aug-2025 29-Aug-2025 Intimation under Regulation 30 of SEBI(LODR) Regulations, 2015 as attached.

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew